Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004


Unal S., GARCIA-RODRIGUEZ J.

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, vol.53, no.4, pp.265-271, 2005 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 53 Issue: 4
  • Publication Date: 2005
  • Doi Number: 10.1016/j.diagmicrobio.2005.10.002
  • Journal Name: DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.265-271
  • Keywords: Acinetobacter spp., meropenem, MYSTIC, Pseudomonas aeruginosa, susceptibility, INTENSIVE-CARE UNITS, TEST INFORMATION COLLECTION, PHARMACODYNAMIC TARGET ATTAINMENT, GRAM-NEGATIVE BACILLI, ANTIMICROBIAL RESISTANCE, ANTIBIOTIC-RESISTANCE, NOSOCOMIAL PATHOGENS, BACTERIAL-RESISTANCE, SURVEILLANCE PROGRAM, MEDICAL-CENTERS

Abstract

This study examines the susceptibilities of meropenem and other broad-spectrum antimicrobials tested against bacterial isolates collected from hospitalized patients during 2002-2004 from worldwide medical centers participating in the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program. The in vitro activity of meropenem and 5 comparator antimicrobial agents was assessed against Pseudomonas aeruginosa and Acinetobacter spp. Generally, the susceptibility of Australasian and North American isolates was higher than that of the European and South American isolates. The rank order of activity of the antimicrobial agents tested against a worldwide collection of P aeruginosa was piperacillin/tazobactam (77.7% susceptible) > meropenem (75.4%) > ceftazidime (70.0%) > imipenem (69.7%) > gentamicin (66.1%) > ciprofloxacin (62.0%). Against a worldwide collection of Acinetobacter spp. meropenem (76.1% susceptible) was the most active compound followed by imipenem (74.7%) > gentarnicin (51.9%) > ciprofloxacin (40.5%) > piperacillin/tazobactam (39.8%) > ceftazidime (38.1%). The carbapenems appear to be a valuable option for the treatment of serious nosocomial infections caused by P aeruginosa or Acinetobacter spp. over a broad geographical region. (c) 2005 Elsevier Inc. All rights reserved.